TP53 and neoplasm: Challenges include the low efficiency of small-molecule reactivators, whether mutp53 regains its wild-type conformation with the help of these drugs and whether the effect is sustained or temporary, the unclear levels of p53 restoration required and the impact of tumor heterogeneity and resistance on efficacy.